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ARAIIA]\:
Sila pastikan bahawa kertas soalan mengandungi TUJUH (7) muka surat yang bercetak
sebelum anda memulakan peperiksaan.
Jawab TIGA (3) soalan satraja. Soalan I dan 2 adalah Wajib. Pilih SATU soalan lagi
daripada yang lain. Rancangkan masa anda secara teliti. Hadkan masa anda kepada 2
jam sahaja untuk soalan 1.
BAHAGIAN A: Jawab 2 soalan sahaja
Soalan 1: (Wajib)
Baca kes di dalam appendik I secara teliti. Selesaikan kes tersebut dengan menggunakan
soalan-soalan berikut sebagai garispanduan:
(a)
(b)
(c)
Apakah bennrk saluran pengedaran bagi industri farmasi di Malaysia.
Apakah kedudukan pesaingan Prime Pharmaceutical (M) di dalam industri
tersebut. Apakah kekuatan dan kelemahanrrya? Bagaimanakatr faktor-faktor ini
memberikan kesan terhadap pemilihan saluran pengedarannya.
Apakah kebaikan dan keburukannya menggrurakan saluran pengedaran sendiri?
Apakah faktor-faktor yang perlu dipertimbangkan di dalam memilih saluran
pengedaran yang sesuai untuk syarikat ini.
Apakah jenis firngsi/perkhidmatan PMR berikan kepada Prime Malaysia dan
pelanggan-pelanggannya. Yang manakah di antara fungsi/perkhidmatan yang
boleh dikendalikan sendiri oleh Prime melalui saluran pengedarannya.
Wajarkatr Prime Malaysia membatalkan perjanjian pengedaran dengan MTR.
[50 markah]
...2/-
(d)
(e)
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Soalan 2: (Wajib)
"Bersaing di peringkat dunia - adalah komitmen kita" ialah sebahagian daripada
pernyataan misi korporat Universiti Sains Malaysia. Sebagai Pengerusi Ahli Lembaga
Pengaratr Universiti Sains Malaysia, anda telah diminta untuk menyediakan perancangan
pemasaran untuk universiti ini. Bincangkan isu-isu pemasaran yang perlu diberikan
perhatian dan bagaimanakah perancangan pemasaran perlu dilaksanakan untuk
merealisasikan pencapaian missi ini.
[30 markah]
BAHAGIAN B : Pilih satu soalan sahaja
Soalan 3:
"Perlakuan Pengguna merupakan hasilan pertembungan di antara individu dan faktor-
fbktor persekitaran". Apakah yang anda faham tentang pernyataan ini? Bincangkan?
[20 markah]
Soalan 4:
(a) Huraikan kenapakah penyelidikan pemasaran penting kepada sesebuah
organisasi?
(b) Bincangkan proses yang terlibat untuk mengendalikan penyelidikan pemasaran.
[20 markah]
Soalan 5:
Kenalpastikan dan bincangkan dengan menggunakan contoh pada setiap tahap proses
pembentukan produk/perkhidmatan baru?
[20 markah]
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identifying new markets. A research area-was given priority if itsatisfied an urgent
medic;l n;ed. The firm set market leadership in a priority research area as a primary
corporate objective.
Rather than enter into licensing agreements, PPUSA preferred to establish opera-
tions in other countries especially in Southeast Asia. Expansion of productive-caPac-
ity and R&D took the bulk of capital expenditures both in the u.s. and abroad. From
fgAS to tgg0, contributions frornforeign operations averaged 24.5% of total revenues'
Prime focused operations and resources in the cardiovascular, respiratory, gastro'
intestinal, infection and local anesthetics segments' The main thrust of PPUSA and all
subsidiaries was to "product/markets" with consistent and uniform product strate-
gies. Introduction of new products and branching into new markets were the main
luenues for profitability and growth. These objectives were accomplished by research
for new products and innovative proiects'
Company Background in MalaYsia
prime Pharmaceuticals Malaysia (M) Sdn. Bhd., wholly owned by PPUSA, formally
started its Malaysian operations in 1981 by marketing products imported from its
oarent. Companv obiectives includedl maintenance of Prime's premier position in
Ithical pharmu..uti.ilt; .oncentration on the private sector to increase use of Prime's
produ.it; increase use of Prime's products inall sectors of the markeu and involve-
ment in doctor training via its educational program.
Several products w-ere launched in the ensuing years; 1984 sales were RM8.7 mil-
lion, up 407o from 1981. Growth slowed in 1985 (sales: RM9.4 million)but picked up
the ioliowing year to RMl1.28 million. The late 1980s were a slow growth period, but
sales spurted to RM20.2 million in 1990 (Table 1)'
Table 1: Historical and Targeted Sales
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During the nnnagement stalf meeting in lanunry 7997, Mannging Director Oliaer Snith,
anrounced the sales growth ob jectiue set by head office for the decade just starling: "With nnjor
new product introductions scheduled in our market in the next few years, and with continuing
supportftotnthenolher cotnpany,weare co,nmitteil to atargeted growthrate ol2|Yop.n. in the
near and nedium ternts and 30%" long term." Sntith snid that although these numbers appeared
optitnistic, cotrsidering the preuious three years' grouth rates, he also knew that, giaen the
corttirutirtg slrong perfornrnnce of the Malnysian economy anil the increasing health care
awareness in aII sectors of the country, these targets were achieaable. He was considering stra-
tegic narketing noues to furlher strengthen Prime Pharmaceuticals Malaysia's conryetitiae
position anil enable it to meet managenent expectations.
The frst moue Snith hnd in uind was to discontinue Prine's exclusiue distribution ar-
rangententswithM.T. Rollitrs(MTR), infauor of self-distribution. Hewonderedif thismooe
would haae the support of the hend offce. ln any eaent, he knao that his reconnrendation uould
weigh heatsily in the finnl decision.
RX,6
CompanyBackground
Prime Pharmaceuticals USA (PPUSA) was established in the early 1900s. Focusing
efforts and resources on R&D it developed a wide array of products. Through the
years, PPUSA expanded its operations to different parts of the globe. Prime's organiza-
tion was functionally structured. Divisions included the major subgroups: marketing,
finance R&D and manufacturing and logistics. Marketing and R&D were the leading
functions; other areas provided support.
PPUSA's corporate policies reflected its emphasis on R&D; R&D budgets were re-
quired to be 20% of sales; thus, growth was pursued by developing new products and
F{
Sales
RM million
Increase
Year
SaIes
RM million
Increase
Year
1989
1990
1991'
7992'
1993'
9.0
19.5
25.0
25.0
30.0
16.90
20.20
25.00
31.25
40.60
8.0
20.0
28.5
7.O
8.70
9.40
1r.28
14.50
15.50
t984
1985
t986
1987
1988
'Targeted
PPUSA decided on all product launcl'res based on corporate product policies. Deci
,ions muae by the local .brnpurly had to fall within boundaries set by PPUSA's phi-
losophy and iolicies. Internotional operations emphasized "product marketing" and
distribution following strict PPUSA guidelines, including centralization of licensin&
finances and investments. Company-growth targets were set above industry growth'
The company secured market share iiformation from market research conducted by
,r.u"y oigu^izations but closely guarded this data from competitors. Profits were
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repatriated largely through transfer pricing; contribution to the parent was pegged at
25o/o oI sales,
The Malaysian Pharmaceutical Industry
In Malaysia, major pharmaceutical companies engaged only in formulation com-
pounding and marketing. The marketing function could be further segregated into
promotiorl distribution, wholesaling, retailing and the tendering agents in govem_
ment medical facilitie!.
The Malaysian pharmaceutical industry was generally divided between the gov-
emment and private sectors:
I Governnrent purchases rvere m.1de through General Medical Stores (GMS). The
GMS, under the control of the Ministry of Health (MoH), facilitated collective
government purchases of medicines.
r Local purchase orders (LPos) referred to public hoipitals' own purchases lvhen
demand exceeded GMS supply and/or special drugs were needed. Hospital
purchasirrg committees decided on LPOs subject to GMS regulations.
r The private sector comprised 280 private companies which logether vied for the
RM488-RM517 million market (including government purchases). Local com-
panies included 23 manufacturers and 59 distributorships. From tinre to time,
distributors also acted as marketing arms. Several tendering agents dealt mainly
. with government hospitals. The remainder were small firms engaged in minor
operations.
Industry Composition
Most pharmaceutical companies were concentrated in selangor, and Kuala Lumpur,
Malaysia's capital.r A high percent (37.5%) of all Malaysian doctors rvere located in
Selangor and in the capital; other important areas were penang and perak. Customers
were concentrated in selangor and Perak states and Kuala Lumpur. These areat to-
gether with Penang, Johore, sabah and sarawak accounted for tio% to 90% of custo-
nlers.
clinics. Malaysian doctors dispensed drugs through their clinics; by law, doctors had
tote present whenever the clinic was open. In 1990, this channei represented 55%(RM268 million) of total purchases. stocks were purchased primarily from wholesale
pharmacies. Average inventory (RM2O000 to RM3e000) turnover was three tinres per
annum. Revenue estimates for clinics were RM10O000 to RM250,000 annually; profit
margins were estimated at almost50%.
Pharmacies' Pharmacies were either retailers, wholesalers or both; in Malaysia, the
majority fulfilled both functions. Together, pharmacies accountecl for 7% (itM34.15
rAlthough geographically located in Selangor, Ku.rl.r Lumpur was part of the l:cderal Territory.
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nnillion) of total industry sales. A pharmacy with RM2.5 miUion sales volume required
,8tr4300000 equity for its operations.
pistributors. Distribution agreements between pharmaceutical companies and their
distributing agents varied. Typically they fell into one of three categories:
r Distribution and promotion of the principal's products. The distributor was
responsible for all aspects of distribution (e.g., storage, delivery/physical trans-
fer of goods, receiving orders, order processing, billing, collection of payment,
credit l'randling, providing the principal lvith sales and market information).
Promotion involved detailing calls on doctors and advertising. The principal's
role was limited to supply.
r Distribrrtion of the principal's products. The distributor was responsible for all
aspects of distribution but the pharmaceutical company promoted its own
products.
r Physical transfer of principal's products. The distributor warehoused and deliv-
ered the principal's products. Other aspects of distribution and marketing were
undertaken by the pharmaceutical company.
Pharmaceutical companies paid from 9% to 2l% of sales for distribution seryices.
Although 59 distributors carried pharmaceutical products, 90% of distribrrtion lvas
handled by three distributors; their revenues ranged from RM100 million to RM400
million. Low gross and net margins earned by distributors rvere compensated by high
volunre sales. In addition, through licensing and representation of parent companies,
these major clistributors inrported and carried products of other pharmaceutical corh-
panies. Payment periods for distributors ranged from 45 to 9€ days from receipt of
stocks.
Tendering agents. Up to 18% (RM90 nrillion) of industry sales was to tendering
agents, middlemen who offered tenders to the GMS, and hospitals authorized to make
LPOs on government purchases not exceeding RM10000. Mark-up averaged 3%; aver-
age revenues for tendering agents were RM5 million, net profit, RM22000.
The flolv of goods in the pharmaceutical industry is sholvn in Figure 1. Competition
for profits, nrarket share and brand awareness took place where the arrows meet.
Mark-up was highest at the level of clinics, hospitalg druggists and retail pharmacieq
lowest between the distributors and its principals.
Marketing Practices
Before 1984, roughly 20,000 different drugs were offered to the Malaysian market; for
example, the antibiotic ampicillin alone was offered as 1.10 different brands. In 1985,
the Drug Control Authority (DCA) was established to authorize the use of drugs in
Malaysia. By 1990,4,000 drugs had been approved by the DCA.
Stiff conrpetition lirnited price increases. Since 1989, prices had risen by 8% to 10%,
driven by inflation, rising expenses and the increased cost of manufactured goods.
I
ro
=f,
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rf) However, clinic treatment costs had not risen during the previous eight years. Drulprices were not subject to regulation in Malaysia and the medical care and heal1f,
expenses price index increased only by 5.5% in 1989.
Figure 1; Flow of Goods in the Malaysian Pharmaceutical Industry
. 
Product advertising in Malaysia was regulated by the Medicine and Advertising
Act. Promotional practices included:
r Missionary sales generated by medical representatives;I Printed promotional materials distributed to customers;
r Discounts given to customers;
r Sample distributiop to customers;
r Advertising for over-the-counter products;
r Consumer product education through symposia, congresses and the like;I Generation of purchases via local and overseas trips;I In certain cases, direct cash donations to charitable funds.
Manpower. Medical representatives were integral components of the industry, Their
primary function was detailing approaching doctors or pharmacists and introducing
the company's products. Signed oiders were executed through distributors or phar.
macies. Product deliveries were usually made within 72 hours of order placement.
Sales teams cover different product groups. On average, medical representatives
visited clients every 60 to 90 days. However, visits were sometimes made twice or three
timespermonth. Detailing coverage rangedfromg. o/o to 51.4%; no company reached
100% market coverage since most focused efforts on specific market segments.
440 ra* VIII Malaysia
I
\o
a
a
1990
Crrdiorhscular
Comrnerical
LPO'
Tender
Subtotal
tnlcdion
Commerical
LPO
Tender
Subtotal
ResPiretory
Commerical
LPO
Tender
Subtotal
Local anesthetic medical
Commerical
LPO
Subtotal
Local anesthetic dental
Commerical
LPO
Tender
Subtotal
GasEeinteslinal
Comcrical
LPO
Subtotal
Othen
Commerical
LPO'
Tender
Subtotal
Total commcrical
Toral LPO
Total tender
Total
1,410,887
26,787
5,574,303
1,41r,696
r,453
2,5t9,569
,frJTE
1,469,720
10.1,345
1.ot4,292
1,663,882
r3,0E9
5,545,690
7.222.66r
t,720,277
16,123
4,043,785
57EdiEs
1,643,395
127,299
890,100
2.660.794
7t6,666
4r4,071
1.130.677
404,744
32,srl
1.374.075
r.610.730
650,5t5
3,224
653.739
2r.9
1,000.8
60.6
--an
I l.l
22.0
-12.2
t4.2
280.2
2!-6
u,5
374.E
936.7
376.0
14.4
75.0
17.9
-51.1
-o.5
3.0
7.4
52.0
20.0
6U,429 3.1
293,135 1.4
Pharmaceuticals Malaysia
Perfonnance
by product setments. The cardiovascular, inJection and resPiratgg,Ptg9Y.:
were the lirgest sales contributors to Prime Malaysia, aboutTTvo of total
sales (Table t). However, in l99O Srowth was only siSnificant in infection
Eicept for cardiovascular Productt Prime Malaysia's top sellets registered
rates than the induitry. Prime's highest growth rate (376%) was in the
iiable z, Sales by Product Segment, 1989, 1990 (RM)
o/" o( total o/o lncrease
8.2
0.06
27.4
35.7
8.5
0.1
20.0
20t-
8.1
0.6
4.4
l;L$
3.5
2.0
5-6
2.0
0.2
6,0
nq
3.2
0.0r
3-2
81,018 0.4 47.6
1.008-s82 t5 15.1
7,422,908 36.6 21.6
899.392 4.4 54.8
10,331,320 11,935,368 58.9 15 5
r'.sbf,sr 2o.2s7,s68 Loq! w
1 989
6ffi,769
272,359
933.128
354,032
8,552
l_068.603
1.431.t87
137,077
3ll
Lg]24
554,481
167,264
154,553
876.298
6,084,402
581,071
'Lmal purcha* ordcrs
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sales bystate. In 199o sales growth varied considerably by state (Table 3). For exam-
ple, inSelangor, P,enang and Perlis, salesincreased byoverS}Yo,However,this growt[
was offset by declines insuch areas as Negri Sembilin and rerengganu. poor pelform-
ance in these states was attributed to lack of manpower; one peiion covere& several
product ranges and segments in several states.
Table 3: Sales by State, 1989, 1990 (RM)
1989 1990 % of total 7o increase o/o of industrv
sible for three product categories covered by two area managers and one medical
representative.
I Prime Task Force: a specialist group concentrating on existing selected products
that also took charge of other product launches. A single product specialist and
six medical representatives comprised this division.
The primary function of Prime's medical representatives was detailing doctors and
pharmacists, introducing and promoting Prime's products. They also booked orders;
ihese were turned over to M.T. Rollins for processing, delivery, billing and collection.
Eigu;re 2t Organization Chart
Distribution
Prime Malaysia contracted the services of M.T. Rollins (MTR) for distributing its prod-
ucts. MTR was one of Malaysia's leading distributors of pharnraceutical products; it
had five offices and stores across the country.3 From these offices it handled product
distribution for over 100 companies in Malaysia, including Prime. In addition to phar-
maceutical products, MTR distributed consumer and agro-chemical goods. It employed
t In addition to thc nrain oflice in Kuala Lurnpur scrving ccntral lllalaysia rverc branchcs in Johor
Bahru (south Malaysia), Pcrak (nrrrth o[ Kualr Lurnpur), Penang (north Malavsia) and S.rbah (Easl
Malaysi.r).
East Malaysia
Sabah
Sararvak
Brunei
Subtotal
West Malaysia
Fcdcral Tcrritory
Selangor
Iohor
Pahang
tvla lacca
Negri Scmbilan
Kelantan
Tercngganu
Kedah
Pcrak
Perlis
Penang
Subtotal
360,03s
475,790
12,1.403
960.228
1,3.19,355
1,143,809
474,772
132,390
158,606
174,562
212,539
r34,038
277,462
752,233
12,351
762,129
5.584.255
r0.372.8r8
474,683
530,906
170.426
1. I 76.0 l5
1,842,205
r,803,461
682,065
148,594
202,572
"t77,826
265,919
132,761
318,177
847,199
41,907
r.167 .955
7.624.0J1
I 1.467.510
3 r.8
I t.6
37.O22.tr 1s.4
36.5
57.7
43,7
12.2
27.7
-7.6
25.1
- 
1.4
14.7
12.6
239.3
53.?
35.3 12.5
10.6 12.5
2.3
2.6
0.!
5=E
9.1
8.9
3.4
0.7
1.0
0.8
1.3
0.7
1.6
0.2
J,t
3Z-6
ID
F{
Sales and Marketing Organization.
Sales teams were divided into Private, Hospital and East Malaysian Divisions ancl the
Prime Task Force (Figure 2).
t Private: responsible for three product categories and divided geographically into
North, central, East coast and south Malaysia. This clivisiorihad fot,r area
managers and 11 medical representatives.
r Hospital: responsible for two product categories and divided into the Nortfiern
Central/south Malaysia areas. This division was managed by two area nranag-
ers and eight medical representatives.
r East Malaysia: included sabah, sarawak and Brunei.2 This division was respon-
I Although Brunci was not part of lvlalaysia, salcs wcre handled by this division.
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31 sales representatives (supervised by nine sales supervisors) to call on customers fs1'
orderbooking and collection ofpayment forall purchases.
The dishibution arangementbetween Prime and MTR called forMTRto Provide
storage, order taking and processing, delivery, credit, billing and supply of sales and
delivery information. MTiTs fees averaged 9% of sales. MTR's 1990 purchases frorl'
Prime were RM12.4 million. MTR paid Prirne within 50 days from receipt of stocls.i
MTR's customers received 30- to 60-day credit for all purchases; credit limits extended
ranged from RM2,500 to RM20,000. MTR's 1990 sales exceeded RM400 million'
Deliveries were made by vans within city limits and in areas covered by NfIR'
branches and stores, If possible, deliveries were made in 48 hours; in some caseql
delivery could be delayed up to one week by transport problems. Lorry services (RM2
per package) were available outside these areas: delivery was 48 hours to one week. 
'
Prime Considers Qelf-distribution
Although MTR had performed creditably in distributing Prime's productt its exten-
sive ptoduct line included pharmaceuticals, agro-chemicals and consumer items. As a
result, Prime executives believed it did not provide adequate attention and concentra-
tion on a particular product group such as Prime's, Moreover, it appeared that
self-distribution wouid enable Prime to save on distribution costs as sales volume
grew. These savings could be reinvested in additional medical representatives to im-
ptove Prime's market penetration and senricing.
If Prime terminated MTR's services and commenced self-distributio& it would have
to set up a minimum of four distribution units across Malaysia, in addition to the
Kuala Lumpur-bas?d unit, to maintain Prime's distribution status and delivery stan'
dards. (table4 details the annual estimated cost of one distribution unit and associated
capital requirements.) These distribution units would handle storage, order processing,
billing and delivery and cotlection of accounts. Because of Prime's inexperience in
distribution" an experienced manager in inventory and distribution management
would be required. Smith believed that Prime's good reputation and industry status
would allow him to attract qualified applicants. He estimated that a suitable distribu-
tion manager would cost from RM30,000 to RM4&000 per annum.
Smith's tentative plan was to assign outlets covered by MTR to Prime medical rep-
resentatives for order booking; orders would be passed to distribution units for
processing and delivery. Collection of accounts would be handled by Prime's sales
force. Since the proposed change would entail additional new responsibilities,
particularly credit management and collectiory Smith wondered how the sales force
would adjust and react, He was also concerned about the degree of orientation and
training the sales force would require and who would accept this responsibility.
Mostly, since the sales force's primary responsibility was demand creation for Prime
products among physicians, he wondered how distribution responsibilities would
affect its performance in the physician's clinic.
Smith was also concerned about the reaction the proposed change would have on
Prime's working relations with outletq inasmuch as many had long-term working
relationships with MTR. Would they be as cooperative in placing their orders for
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Estimated Cost of One Distribution Unit' 1991
L$urance Premlum
Licence fee
Postage
Petrol and traveling
Overtime
Office uPkeeP
Rental of warehouse
Stationery
Telephone charges
Transport charges
Courier charges
Grand total
Capitalization
Two vans
Deposits
Renovations
Equipment
Miscellaneous
Total
2,400
13,650
55,250
310
1,000
14,000
1,500
2,500
24,000
3,000
5,000
1000
3,000
235,610
80,000
10,000
50,000
r00,000
60,000
300,000
Primeproducts,maintainingadequateinventories'providingprominentandad-
eouate display sPace and meeting payment terms as thev werswith 
MTR? Based on
;il;il';i;;auids and urn pra'ciic;s, Prime would offer the same terms:30 days
.r"Jit ,,ii,f., 
" 
g0-day grace peribd. Also in line with industry practice discount terms
;;il'.;.g. rroi isy" t[ is"t , depending on whether purchases were direct or
through wholesalers'
lnadditionto theeconomics,smithbelieved imPortant qualitative factorshad 
tobe
considered. For example, gruli", utt"ntion and concentration on Prime's products 
at
the outlet level mightue ex;edJ ii;h;p;;" t"les organizarion was tully responsible
for dishibution. rhis issue Las particularly important for new product introduction/ 
a
;;;'r;;; 
"f 
growth anJ piofitability for prime. prime medical representatives
ilil;;;;;ia?u.tt".i,,-rtore support (e'g'' maintaining displayceducatin8retail
clerks, assisting i.tr,"ntoty i".tlig 
"?'pt"tl iroducts)' 
Smith also felt that problems in
t.fi".*,trfn.,i back oriers, canillations, ietums and product quality could be more
.ffu.tiJJv t 
""iled on the spot 
by a company representative'
":;ih i;il;;A;;,h; ;[;iages of'setfidisltribution revolved around the sreater
control it allowed management. HJbelieved Prime medical representatives.could 
pro'
videmore and b"U", murtet iJormation thanMTR.Information on competitive activi-
i.r, i.* pi"a"ct inhoductions and trade devetopments would be fed back to market-
ing and necessary 
""ti.;;;;;itry 1-prut""tld' Finallv' self'distribution 
would
present more ioU oppo.ru.,itiJ,' Exilting employeeg as welias People 
ouhide the com-
pany, could fi' n"* op"niig, i[" JitttTuutitnLnits would mike available and could
fi;i;;*;";.i.r,i"g tr,. qiralificationsof some company's personnet to therightiob.
As he contempf"t"a ti"ti*u.r, S.ith tn"* thatiisiecbmmendation would be
criticalfortheMofuyriu.,o,gutti'utio"'sfuture'Healsoknewthatheadofficewould
scrutinize any plan, so it *o"ufa have to be backed up by solid economic analysis'
I
I
I
a
UoFp
F*
I
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